Suppr超能文献

生物制剂:它们在克罗恩病的治疗中能走多远?

Biologics: how far can they go in Crohn's disease?

作者信息

Dunleavy Katie A, Pardi Darrell S

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

出版信息

Gastroenterol Rep (Oxf). 2022 Sep 29;10:goac049. doi: 10.1093/gastro/goac049. eCollection 2022.

Abstract

Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.

摘要

克罗恩病是一种慢性胃肠道炎症性疾病,其特征为病情反复发作和缓解。随着疾病机制得到更深入的阐释,可用的生物疗法数量显著增加。本文总结并综合了美国食品药品监督管理局目前批准的用于治疗克罗恩病的生物疗法,并探讨了随着新型生物制剂进入市场,药物治疗的定位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3c/9522383/9d4b10ccf62f/goac049f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验